LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced its participation in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13-14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event will gather students, faculty, and professionals from systems engineering and healthcare disciplines, including pharmacy, dentistry, and laboratory sciences, to explore practical applications of AI and automation in medical and technical settings.
Representing LataMed AI will be Dr. Kevin Rodan Levy, CEO, and Carlos Pena, CFO, who plan to address the evolving role of AI in healthcare, systems engineering, digital infrastructure, and professional decision-making. The company intends to discuss how AI-supported tools can assist healthcare professionals with medical data evaluation, clinical workflows, and operational efficiency, as well as how automation may enhance the organization and reliability of technology systems in complex environments.
A central theme of the presentation will be the importance of maintaining qualified professional oversight when implementing AI. LataMed AI emphasizes that its technologies are designed to augment human capabilities and support informed decision-making, not replace the independent judgment of healthcare professionals, engineers, or laboratory personnel. Additional topics will cover AI integration into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations for developing and deploying technology in healthcare settings.
The company also plans to discuss its ongoing development of CardioAI, PulmoAI, and NeuroAI—AI-supported platforms aimed at assisting healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information. These platforms are subject to continued development, testing, regulatory requirements, and commercial implementation.
“Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering,” said Dr. Kevin Rodan Levy. “Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America.”
LataMed AI believes that engagement with universities and educational institutions can raise awareness of emerging healthcare technologies, encourage responsible discussions about AI, and strengthen relationships with future professionals. The company views this participation as a chance to better understand the perspectives of students, educators, and technical experts as it continues to develop digital health solutions for the region.
This participation aligns with LataMed AI’s broader strategy of supporting education, professional collaboration, and the responsible adoption of digital healthcare infrastructure in Latin America. The company intends to evaluate further opportunities to participate in academic, healthcare, and technology forums that align with its objectives.
It is important to note that participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria, nor does it guarantee future collaborations, regulatory approvals, or financial benefits. For more information, visit https://latamed.ai or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
